With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today)

LSD Deal Brings Amicus $50M Now, $390M Later

Nov. 14, 2007

By Trista Morrison

LSD Deal Brings Amicus $50M Now, $390M Later

Nov. 14, 2007

By Trista Morrison

Ambit's Series D Raises $50M For Kinase Inhibitor Program

Nov. 14, 2007

By Trista Morrison

With one kinase inhibitor in the clinic and two more in the queue, Ambit Biosciences Corp. raised $49.3 million in a Series D financing round. (BioWorld Today)

Synta's Elesclomol In Pivotal Study In Melanoma Patients

Nov. 13, 2007

By Trista Morrison

A month after signing a billion-dollar deal with GlaxoSmithKline plc for elesclomol (formerly STA-4783), Synta Pharmaceuticals Corp. kicked off a pivotal Phase III trial of the drug in metastatic melanoma. (BioWorld Today)

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...